Will continue to pursue inorganic growth in India & US: Torrent Pharma

Samir Mehta

Chairman | Torrent Pharma

• Will continue to pursue inorganic growth in India & US: Torrent Pharma

• Eyeing inorganic opportunities to increase growth: Torrent

The big story from deal street is that Torrent Pharmaceuticals will acquire Unichem Laboratories' branded formulation business in India and Nepal. Torrent will spend Rs 3,600 crore for the acquisition, which is expected to close by the end of this year.

In an interview to CNBC-TV18's Ekta Batra and Vikas Dandekar, the Chairman of Torrent Pharma, Samir Mehta spoke about the rationale behind the deal and where it would take the company in the Indian pharmaceutical market.

Mehta said that Torrent will become fifth largest company in India, with Unichem acquisition, with 3.4 percent market share.

He further said that Unichem has strong equity in the doctor community.

Unichem acquisition will further help strengthen India position, he said.

He mentioned that India has and will remain a priority market and US will be the next most important market after India.

According to him, Indian pharma market is large and therefore, he expects double-digit growth.

Talking about growth, he said we will continue to pursue inorganic growth in India, US and EU.